![Luke Walker](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Luke Walker
Direttore Tecnico/Scientifico/R&S presso HARPOON THERAPEUTICS, INC.
Patrimonio netto: 296 447 $ in data 30/06/2024
Profilo
Luke N.
Walker is an Independent Director at Zentalis Pharmaceuticals, Inc. since 2024 and the Chief Medical Officer at Harpoon Therapeutics, Inc. since 2022.
Previously, Dr. Walker held positions as Vice President-Clinical Development at Seagen Inc. and Cascadian Therapeutics LLC.
Dr. Walker completed undergraduate, graduate, and doctorate degrees at the University of Oklahoma.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
24/05/2024 | 72 481 ( 0.10% ) | 296 447 $ | 30/06/2024 |
Posizioni attive di Luke Walker
Società | Posizione | Inizio |
---|---|---|
HARPOON THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 03/10/2022 |
ZENTALIS PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 29/05/2024 |
Precedenti posizioni note di Luke Walker
Società | Posizione | Fine |
---|---|---|
CASCADIAN THERAPEUTICS INC (USA) | Direttore Tecnico/Scientifico/R&S | 09/03/2018 |
SEAGEN INC. | Corporate Officer/Principal | - |
Formazione di Luke Walker
University of Oklahoma | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
ZENTALIS PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 3 |
---|---|
Cascadian Therapeutics LLC
![]() Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC was a clinical-stage biopharmaceutical company, which focused on the development of therapeutic products for the treatment of cancer. Its product ONT-380, was an orally active and selective small-molecule HER2 inhibitor. The firm also developed preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on August 23, 1985 and was headquartered in Bothell, WA. | Health Technology |
Harpoon Therapeutics, Inc.
![]() Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA. | Health Technology |
Seagen Inc.
![]() Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
- Borsa valori
- Insiders
- Luke Walker